uveitis
Conditions
Interventions
Case series:injection of Conbercept
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Signed informed consent, and are willing to follow-up in accordance with the prescribed test time; 2. Aged 18~60 years old male and female; 3. The target eye must meet the following requirements: (1) The clinical diagnosis is non-infectious posterior uveitis such as retinal vasculitis, Behcet's disease uveitis, Koyanagihara disease, multifocal choroiditis, purulent choroiditis, punctate choroidal lesions, etc. (2) FFA/OCT shows the presence of cystoid macular edema (CME) and/or retinal/choroidal neovascularization (RNV/CNV) (3) A history of noninfectious uveitis with quiescent inflammation for at least 2 months prior to study entry, a stable immunosuppressive regimen (including systemic and topical treatments) for at least 2 months prior to injection (4) Eye medium is clear; (5) BCVA value is 20/40 to 20/400 in the study eye.
Exclusion criteria
Exclusion criteria: 1. Study eye has received PDT treatment; central recess laser treatment (including foveal or paracentral photocoagulation, grid-like photocoagulation, panretinal photocoagulation) or TTT; 2. Study eye has undergone corneal transplantation; 3. The investigator judges that the existing eye disease of the study eye affects the detection of the macula or affects the central vision; 4. Vitreous hemorrhage in the study eye; 5. Previous intravitreal anti-VEGF drugs injection in study eye within 3 months of study injection; 6. Fibrotic scar or RPE tear in the central fove of the study eye; 7. Intraocular surgery within the past 3 months; 8. Previous vitrectomy in study eye; 9. Uncontrolled inflammation; 10. Uncontrolled glaucoma; 11. The study eye is aphakic or the posterior capsule is ruptured; 12. Ocular tumor in study eye; 13. Treatment with anti-VEGF drugs within 6 weeks before enrollment; 14. Allergic reactions to sodium fluorescein or diagnostic protein products; 15. Diabetic patients with uncontrolled blood glucose; 16. Surgery within the past 3 months; 17. Infectious diseases requiring oral, intramuscular or intravenous administration; 18. A history of myocardial infarction and/or cerebral infarction within the past 6 months; 19. Active diffuse intravascular coagulation and significant bleeding tendency within the past 3 months; 20. Hypertensive patients with poor blood pressure control; 21. Any clinical problems that cannot be controlled; 22. There are any clinical problems that cannot be controlled; 23. Those who do not use effective contraceptives; 24. Pregnancy; 25. Clinical trials within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA;CMT; | — |
Countries
China
Contacts
Public ContactPeizeng Yang
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed